This site uses cookies. For more information, please see our
Privacy Policy
Agree
About
Company
Board
Management
Products
Trogarzo® IV Infusion
Trogarzo® IV Push
TMB-365
TMB-365/TMB-380 (TMB-365 and TMB-380 combination)
Antibody-Drug Conjugates, ADCs
CDMO Service
Contract Development and Manufacturing Service (CDMO)
Partners
News
Activity
Investor Relations
Company
Company Profile
Company Presentation
Corparate Governance
Organization
Board
Committee
Internal Audit
Major Internal Policies
Financials
Monthly Revenue
Financial Reports
Shareholders' Services
Major Shareholders
Dividend Information
Shareholder's Meeting
Sustainable Development
2023 ESG
MENU
(
En
)
En
繁中
Contact CDMO Service
CLOSE
En
繁中
About
Company
Board
Management
Products
Trogarzo® IV Infusion
Trogarzo® IV Push
TMB-365
TMB-365/TMB-380 (TMB-365 and TMB-380 combination)
Antibody-Drug Conjugates, ADCs
CDMO Service
Contract Development and Manufacturing Service (CDMO)
Partners
News
Activity
Investor Relations
Company
Company Profile
Company Presentation
Corparate Governance
Organization
Board
Committee
Internal Audit
Major Internal Policies
Financials
Monthly Revenue
Financial Reports
Shareholders' Services
Major Shareholders
Dividend Information
Shareholder's Meeting
Sustainable Development
2023 ESG
2024
Home
News
Recent News
2024
News
Recent News
2024
2023
Recent News > 2024
Recent News > 2023
2024/04/09
20240409 Results Conference Video
2024/04/09
Taimed Biologics And Wuzhou Drug International Trading Co., Ltd. Partner to Commercialize Trogarzo In Hongkong And Macau
2024/03/22
The Company Announces Enrollment of First Patient in Phase 2a Clinical Study of the Long-Acting TMB-365/TMB-380 mAb Combination for the Bi-monthly Maintenance HIV Therapy
2024/03/14
Taimed Biologics And AcedrA Biopharmaceticals Partner to Commercialize Trogarzo In The Middle East And North Africa Region
2024/03/06
CROI 2024 (Updated)
2024/02/21
The Company received patent approval from the Taiwan Intellectual Property Office for improving the pharmacokinetic performance of TMB-365 using histidine modification technology.
2024/02/13
The US FDA grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination therapy for HIV Infection
2024/02/02
The Company received a Japanese patent certificate for improving the pharmacokinetic performance of TMB-365 using histidine modification technology.